Key result
Novel RT-IMSA assay improves EV71 diagnostic sensitivity to ~96% compared to RT-LAMP.
Why the study?
Does the novel RT-IMSA assay improve the detection limit and diagnostic sensitivity for EV71 and CVA16 compared to RT-LAMP and qRT-PCR?
Does the novel RT-IMSA assay improve the detection limit and diagnostic sensitivity for EV71 and CVA16 compared to RT-LAMP and qRT-PCR?
The novel RT-IMSA assay provides a more sensitive and rapid detection method for EV71 and CVA16 compared to existing RT-LAMP assays.
May support faster EV71/CVA16 detection in resource-limited settings; leaves open larger prospective validation before clinical adoption.
Rapid detection of human enterovirus 71 (EV71) and coxsackievirus A16 (CVA16) is important in the early phase of hand-foot-and-mouth disease (HFMD). In this study, we developed and evaluated a novel reverse transcription-isothermal multiple-self-matching-initiated amplification (RT-IMSA) assay for the rapid detection of EV71 and CVA16 by use of reverse transcriptase, together with a strand displacement DNA polymerase. Real-time RT-IMSA assays using a turbidimeter and visual RT-IMSA assays to detect EV71 and CVA16 were established and completed in 1 h, and the reported corresponding real-time reverse transcription-loop-mediated isothermal amplification (RT-LAMP) assays targeting the same regions of the VP1 gene were adopted as parallel tests. Through testing VP1 RNAs transcribed in vitro, the real-time RT-IMSA assays exhibited better linearity of quantification, with R(2) values of 0.952 (for EV71) and 0.967 (for CVA16), than the real-time RT-LAMP assays, which had R(2) values of 0.803 (for EV71) and 0.904 (for CVA16). Additionally, the detection limits of the real-time RT-IMSA assays (approximately 937 for EV71 and 67 for CVA16 copies/reaction) were higher than those of real-time RT-LAMP assays (approximately 3,266 for EV71 and 430 for CVA16 copies/reaction), and similar results were observed in the visual RT-IMSA assays. The new approaches also possess high specificities for the corresponding targets, with no cross-reactivity observed. In clinical assessment, compared to commercial reverse transcription-quantitative PCR (qRT-PCR) kits, the diagnostic sensitivities of the real-time RT-IMSA assays (96.4% for EV71 and 94.6% for CVA16) were higher than those of the real-time RT-LAMP assays (91.1% for EV71 and 90.8% for CVA16). The visual RT-IMSA assays also exhibited the same results. In conclusion, this proof-of-concept study suggests that the novel RT-IMSA assay is superior to the RT-LAMP assay in terms of detection limit and has the potential to rapidly detect EV71 and CVA16 viruses.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2014) studied Hand-foot-and-mouth disease (EV71 and CVA16 infection). Reverse transcription-isothermal multiple-self-matching-initiated amplification (RT-IMSA) assay vs. Reverse transcription-loop-mediated isothermal amplification (RT-LAMP) assay was evaluated on Diagnostic sensitivity for EV71. The novel RT-IMSA assay demonstrated higher diagnostic sensitivity for EV71 (96.4% vs 91.1%) and CVA16 (94.6% vs 90.8%) compared to RT-LAMP, with improved detection limits.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: